

## Supplemental Material 3 – Results

**Table 1. Appraisal of CPGs for Research & Evaluation Instrument AGREE II domain scores (%) and AGREE-REX domain scores (%).**

| Country / Study  | AGREE II domains' scores |                            |                          |                            |                  |                           | AGREE-REX domains' scores |                           |                     |
|--|--------------------------|----------------------------|--------------------------|----------------------------|------------------|---------------------------|---------------------------|---------------------------|---------------------|
|  | 1. Scope and purpose     | 2. Stakeholder involvement | 3. Rigour of development | 4. Clarity of presentation | 5. Applicability | 6. Editorial independence | 1. Clinical applicability | 2. Values and preferences | 3. Implementability |
| Chile, Ministerio de Salud [23]  | 83                       | 76                         | 89                       | 94                         | 57               | 17                        | 33                        | 29                        | 41                  |
| Colombia, Ministerio de Salud [24]   | 100                      | 85                         | 86                       | 100                        | 96               | 92                        | 72                        | 57                        | 67                  |
| United Kingdom, National Institute for Health and Care Excellence [25]   | 89                       | 83                         | 84                       | 81                         | 71               | 75                        | 87                        | 67                        | 75                  |
| Germany, Härter et al. [26]  | 69                       | 78                         | 83                       | 87                         | 58               | 72                        | 61                        | 42                        | 64                  |
| Peru EsSalud [27]  | 72                       | 52                         | 82                       | 87                         | 39               | 67                        | 67                        | 36                        | 50                  |
| USA, Trangle et al. [28]   | 96                       | 78                         | 81                       | 91                         | 72               | 97                        | 55                        | 36                        | 50                  |
| USA, American Psychological Association [29]   | 91                       | 67                         | 81                       | 80                         | 65               | 83                        | 81                        | 44                        | 50                  |
| USA, Management of Major Depressive Disorder Working Group [30]  | 93                       | 76                         | 78                       | 94                         | 38               | 58                        | 67                        | 31                        | 56                  |
| USA, Kaiser Permanente Care Management Institute [31]  | 83                       | 63                         | 76                       | 93                         | 46               | 58                        | 54                        | 25                        | 33                  |
| Spain, García-Herrera Pérez Bryan et al. [32]  | 74                       | 59                         | 72                       | 85                         | 64               | 75                        | 52                        | 26                        | 61                  |
| Spain, Working Group of the Clinical Practice Guideline on the Management of Depression in Adults, Ministry of Health, Social Services and Equality [33] | 94                       | 93                         | 70                       | 91                         | 75               | 53                        | 67                        | 36                        | 67                  |
| Canada, Registered Nurses' Association of Ontario [34]   | 72                       | 74                         | 69                       | 80                         | 76               | 86                        | 57                        | 42                        | 67                  |
| USA, Qaseem et al. [35]  | 80                       | 39                         | 69                       | 70                         | 32               | 67                        | 48                        | 11                        | 33                  |
| Mexico, Instituto Mexicano del Seguro Social [36]  | 87                       | 46                         | 69                       | 83                         | 14               | 67                        | 48                        | 11                        | 42                  |
| Mexico, Secretaría del Salud [37]  | 81                       | 43                         | 69                       | 80                         | 32               | 31                        | 43                        | 11                        | 50                  |
| Mexico, Secretaría del Salud [38]  | 94                       | 56                         | 63                       | 81                         | 42               | 64                        | 43                        | 15                        | 42                  |
| Singapore, Chua et al. [39]  | 78                       | 72                         | 60                       | 89                         | 50               | 28                        | 59                        | 19                        | 44                  |
| Australia, Malhi et al. [40]   | 74                       | 63                         | 58                       | 78                         | 24               | 67                        | 50                        | 22                        | 44                  |

| Country / Study  | AGREE II domains' scores |                            |                          |                            |                  |                           | AGREE-REX domains' scores |                           |                     |
|--|--------------------------|----------------------------|--------------------------|----------------------------|------------------|---------------------------|---------------------------|---------------------------|---------------------|
|  | 1. Scope and purpose     | 2. Stakeholder involvement | 3. Rigour of development | 4. Clarity of presentation | 5. Applicability | 6. Editorial independence | 1. Clinical applicability | 2. Values and preferences | 3. Implementability |
| Michigan Ambulatory Unipolar Depression Guideline [41]                                   | 65                       | 43                         | 57                       | 80                         | 33               | 53                        | 41                        | 28                        | 31                  |
| France, Driot et al. [42]  | 69                       | 30                         | 56                       | 72                         | 11               | 83                        | 35                        | 4                         | 33                  |
| Several countries, Bauer et al. [43]   | 61                       | 54                         | 54                       | 83                         | 32               | 75                        | 39                        | 11                        | 22                  |
| Canada, Kennedy et al. [44]  | 63                       | 48                         | 54                       | 89                         | 26               | 53                        | 44                        | 17                        | 36                  |
| Several countries, Dua et al. [45]   | 69                       | 74                         | 50                       | 74                         | 29               | 75                        | 41                        | 25                        | 47                  |
| USA, McIntyre et al. [46]  | 87                       | 56                         | 48                       | 83                         | 32               | 69                        | 39                        | 21                        | 33                  |
| Several countries, Bauer et al. [47]   | 69                       | 48                         | 47                       | 61                         | 28               | 75                        | 48                        | 15                        | 19                  |
| Malaysia, Malaysian Health Technology Assessment Section [48]                            | 81                       | 50                         | 47                       | 70                         | 54               | 78                        | 59                        | 33                        | 67                  |
| USA, Gelenberg et al. [49]   | 48                       | 43                         | 46                       | 83                         | 44               | 42                        | 59                        | 32                        | 42                  |
| The Netherlands, Nederland Depressie [50]  | 70                       | 70                         | 42                       | 65                         | 22               | 50                        | 28                        | 19                        | 33                  |
| United Kingdom, Cleare et al. [51]   | 67                       | 57                         | 40                       | 69                         | 13               | 58                        | 52                        | 22                        | 33                  |
| Korea, Won et al. [52]   | 57                       | 28                         | 38                       | 67                         | 21               | 44                        | 35                        | 14                        | 42                  |
| Finland, Suomalainen Lääkäri-seura Duodecim [53]   | 50                       | 61                         | 36                       | 65                         | 40               | 56                        | 44                        | 21                        | 50                  |
| USA, Ruberto et al. [54]   | 43                       | 11                         | 35                       | 39                         | 1                | 72                        | 15                        | 4                         | 11                  |
| Canada, CPGs and Protocols Advisory Committee, Ministry of Health, British Columbia [55] | 85                       | 37                         | 35                       | 85                         | 39               | 42                        | 37                        | 21                        | 44                  |
| USA, Giakoumatos and Osser [56]  | 61                       | 19                         | 33                       | 83                         | 26               | 75                        | 30                        | 21                        | 14                  |
| France, Bennabi et al. [57]  | 72                       | 26                         | 31                       | 85                         | 10               | 81                        | 20                        | 8                         | 25                  |
| Saudi Arabia, Okasha et al. [58]   | 44                       | 26                         | 31                       | 61                         | 31               | 33                        | 37                        | 11                        | 31                  |
| Several countries, Dodd S, Mitchell PB, Bauer et al. [59]                                | 72                       | 31                         | 27                       | 57                         | 17               | 25                        | 41                        | 22                        | 31                  |
| Several countries, Bauer et al. [60]   | 56                       | 41                         | 23                       | 76                         | 21               | 50                        | 30                        | 8                         | 36                  |
| France, Bennabi et al. [61]  | 50                       | 33                         | 22                       | 65                         | 13               | 67                        | 39                        | 26                        | 25                  |
| Pharmacological Management of Depression: Japanese Expert Consensus [62]                 | 50                       | 31                         | 21                       | 59                         | 31               | 56                        | 20                        | 24                        | 25                  |
| South Africa, Emsley [63]  | 50                       | 48                         | 19                       | 67                         | 13               | 19                        | 26                        | 12                        | 33                  |
| USA, Connolly and Thase [64]   | 63                       | 17                         | 17                       | 52                         | 13               | 72                        | 15                        | 6                         | 14                  |

| Country / Study   | AGREE II domains' scores |                            |                          |                            |                  |                           | AGREE-REX domains' scores |                           |                     |
|---|--------------------------|----------------------------|--------------------------|----------------------------|------------------|---------------------------|---------------------------|---------------------------|---------------------|
|   | 1. Scope and purpose     | 2. Stakeholder involvement | 3. Rigour of development | 4. Clarity of presentation | 5. Applicability | 6. Editorial independence | 1. Clinical applicability | 2. Values and preferences | 3. Implementability |
| Korea, Wang et al. [65]   | 56                       | 13                         | 17                       | 43                         | 6                | 58                        | 19                        | 10                        | 36                  |
| USA, Park and Zarate [66]   | 33                       | 22                         | 17                       | 50                         | 18               | 31                        | 17                        | 13                        | 14                  |
| Canada, Voineskos et al. [67]   | 44                       | 11                         | 15                       | 50                         | 10               | 22                        | 15                        | 1                         | 17                  |
| USA, Voytenko et al. [68]   | 54                       | 39                         | 15                       | 65                         | 8                | 42                        | 17                        | 8                         | 22                  |
| Poland, Piotrowski et al. [69]  | 54                       | 26                         | 15                       | 72                         | 25               | 50                        | 33                        | 6                         | 14                  |
| Australia, Bayes and Parker [70]  | 46                       | 22                         | 14                       | 48                         | 7                | 33                        | 11                        | 1                         | 11                  |
| Australia, Malhi et al. [71]  | 44                       | 20                         | 13                       | 63                         | 17               | 39                        | 17                        | 7                         | 25                  |
| France, Doumy et al. [72]   | 39                       | 9                          | 13                       | 39                         | 8                | 36                        | 9                         | 3                         | 22                  |
| Canada, Mulsant et al. [73]   | 50                       | 28                         | 13                       | 61                         | 8                | 36                        | 15                        | 11                        | 31                  |
| Depresja oporna na leczenie – zalecenia Konsultanta Krajowego w dziedzinie psychiatrii [74] | 52                       | 22                         | 12                       | 65                         | 36               | 3                         | 24                        | 8                         | 31                  |
| India, Avasthi and Grover [75]  | 70                       | 24                         | 12                       | 80                         | 36               | 0                         | 22                        | 7                         | 31                  |
| Several countries, Möller et al. [76]   | 28                       | 15                         | 12                       | 11                         | 10               | 33                        | 19                        | 14                        | 25                  |
| France, Charpeaud et al. [77]   | 33                       | 13                         | 10                       | 46                         | 10               | 36                        | 13                        | 0                         | 19                  |
| USA, Busch and Sandberg [78]  | 46                       | 11                         | 10                       | 65                         | 15               | 17                        | 19                        | 6                         | 25                  |
| USA, Mathys and Mitchell [79]   | 41                       | 19                         | 8                        | 37                         | 6                | 58                        | 18                        | 3                         | 19                  |
| USA, Taylor [80]  | 41                       | 7                          | 8                        | 57                         | 8                | 33                        | 22                        | 7                         | 33                  |
| Austria, Gartlehner et al. [81]   | 37                       | 26                         | 8                        | 33                         | 14               | 17                        | 18                        | 7                         | 25                  |
| Spain, Pereira Sanchez and Santos [82]  | 54                       | 24                         | 6                        | 61                         | 8                | 33                        | 15                        | 7                         | 22                  |
| India, Gautam et al. [83]   | 39                       | 20                         | 6                        | 57                         | 15               | 0                         | 22                        | 6                         | 25                  |
| USA, Halaris [84]   | 41                       | 17                         | 6                        | 31                         | 13               | 11                        | 18                        | 5                         | 30                  |
| Poland, Patejuk-Mazurek [85]  | 15                       | 6                          | 5                        | 43                         | 17               | 0                         | 7                         | 1                         | 19                  |

### Reference list

1. Ministério da Saúde (BR). *Diretrizes metodológicas: elaboração de diretrizes clínicas* [Internet]. 2. ed. rev., ampl., atual. Brasília, DF: 2020. Available from: <http://conitec.gov.br/images/Relatorios/2021/Diretrizes-Metodologicas->

- [Elaboracao-de-Diretrizes-Clinicas-2020.pdf](#). Accessed March 03, 2021.
2. Fervers B, Burgers JS, Haugh MC, et al. Predictors of high-quality clinical practice guidelines: examples in oncology. *Int J Qual Heal Care*. 2005;17(2):123-132.
  3. Guidelines International Network. *G-I-N PUBLIC Toolkit: Patient and Public Involvement in Guidelines*. Available from: <http://www.gin.net/activities/gin-public/toolkit>.
  4. Molino CGRC, Leite-Santos NC, Gabriel FC, et al. Factors associated with high-quality CPGs for the pharmacologic management of chronic diseases in primary care: a systematic review. *JAMA Intern Med*. 2019;179(4):553-560. doi:10.1001/jamainternmed.2018.7529
  5. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan: a web and mobile app for systematic reviews. *Syst Rev* 2016;5:210. doi:[10.1186/s13643-016-0384-4](https://doi.org/10.1186/s13643-016-0384-4).
  6. [chronide.org](http://www.chronide.org) [Internet]. [place unknown]: Chronide; c2019. Available from: <https://www.chronide.org/>. Accessed Jun 25, 2021.
  7. AGREE Next Steps Consortium. *The AGREE II Instrument* [Electronic version]. [place unknown]: AGREE; 2017. Available from: <http://www.agreetrust.org>. Accessed May 7, 2018.
  8. AGREE-REX Research Team. *The appraisal of CPGs research & evaluation-recommendation excellence (AGREE-REX)* [Internet]. [place unknown]: AGREE; 2019. Available from: <https://www.agreetrust.org/wp-content/uploads/2019/04/AGREE-REX-2019.pdf>. Accessed May 17, 2018.
  9. Institute of Medicine (US). *Clinical practice CPGs we can trust*. Washington, DC: National Academies Press; 2011. doi:[10.17226/13058](https://doi.org/10.17226/13058)
  10. Zafra-Tanaka JH, Goicochea-Lugo S, Villarreal-Zegarra D, Taype-Rondan A. Characteristics and quality of clinical practice CPGs for depression in adults: A scoping review. *BMC Psychiatry*. 2019;19(1):76. doi:[10.1186/s12888-019-2057-z](https://doi.org/10.1186/s12888-019-2057-z)
  11. Gabriel FC, Stein AT, Melo DO, Fontes-Mota GCH, Santos IB, Rodrigues CDS, et al. Recommendations for the pharmacological treatment of treatment-resistant depression: A systematic review protocol. *PLoS One*. 2022; 17(4): e0267323. doi:[10.1371/journal.pone.0267323](https://doi.org/10.1371/journal.pone.0267323)

12. Ministério da Saúde (BR). *Portaria no. 1.083, de 2 de outubro de 2012. Aprova o protocolo clínico e diretrizes terapêuticas da dor crônica* [Internet]. Brasília, DF: Diário Oficial da União; 2012 [cited 2019 Jan 22]. Available from: <http://portalarquivos2.saude.gov.br/images/pdf/2014/abril/02/pcdt-dor- cronica-2012.pdf>. Accessed June 22, 2019.
13. Ministério da Saúde (BR). *Portaria no. 1.266, de 14 de novembro de 2014. Aprova o protocolo clínico e diretrizes terapêuticas da doença de Gaucher*. Brasília, DF: Diário Oficial da União; 2014 [cited 2017 Apr 5]. Available from: <http://portalarquivos.saude.gov.br/images/pdf/2014/dezembro/15/Doen--a-de-Gaucher.pdf>. Accessed April 5, 2017.
14. National Institute for Health and Care Excellence. *Obesity prevention: clinical guideline* [Internet]. [London]: NICE; 13 Dec 2006 [last updated 1 Mar 2015]. Available from: <https://www.nice.org.uk/guidance/cg43/resources/obesity-prevention-975445344709>. Accessed April 5, 2017.
15. Bahn RS, Burch HB, Cooper D, Garber JR, Greenlee MC, Klein I, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American thyroid association and American association of clinical endocrinologists. *Thyroid* 2011;21(6):593-646. doi:[10.1089/thy.2010.0417](https://doi.org/10.1089/thy.2010.0417)
16. Urinary Tract Infection Guideline Team. *Urinary tract infection*. Ann Arbor (MI): University of Michigan Health System; 2011 Jun.
17. *agreetrust.org* [Internet]. [place unknown]: The AGREE Research Trust; c2010. Available from: <https://www.agreetrust.org>
18. Gabriel FC, Melo DO, Fráguas R, Leite-Santos NC, Mantovani da Silva RA, Ribeiro E. Pharmacological treatment of depression: a systematic review comparing clinical practice guideline recommendations. *PLoS One*. 2020;15(4):e0231700. doi:[10.1371/journal.pone.0231700](https://doi.org/10.1371/journal.pone.0231700)
19. The ADAPTE collaboration. *The ADAPTE process: resource toolkit for guideline adaptation*. [place unknown]: ADAPTE Collaboration, 2009. Available from: <https://www.g-i-n.net/document-store/working-groups-documents/adaptation/adapte-resource-toolkit- guideline-adaptation-2-0.pdf>. Accessed Apr 3, 2017.
20. Acuña-Izcaray A, Sánchez-Angarita E, Plaza V, Rodrigo G, Montes de Oca M, Gich I, et al. Quality assessment of asthma clinical practice guidelines: a systematic appraisal. *Chest*. 2013;144:390-7. doi:[10.1378/chest.12-2005](https://doi.org/10.1378/chest.12-2005).

21. Arevalo-Rodriguez I, Pedraza OL, Rodríguez A, Sánchez E, Gich I, Solà I, et al. Alzheimer's disease dementia guidelines for diagnostic testing: a systematic review. *Am J Alzheimers Dis Other Demen.* 2013;28:111-9. doi:10.1177/1533317512470209
22. Watine J, Friedberg B, Nagy E, Onody R, Oosterhuis W, Bunting PS, et al. Conflict between guideline methodologic quality and recommendation validity: a potential problem for practitioners. *Clin Chem.* 2006;52:65-72. doi:10.1177/1533317512470209
23. Ministerio de Salud (CL). *Depresión em personas de 15 años y más.* Santiago: Minsal; 2013.
24. Ministerio de Salud (COL). *Detección temprana y diagnóstico del episodio depresivo y trastorno depresivo recurrente en adultos: atención integral de los adultos con diagnóstico de episodio depresivo o trastorno depresivo recurrente: Guía de práctica clínica.* Bogotá: Minsalud; 2013. Available from: <http://www.iets.org.co/reportes-iets/Documentacin%20Reportes/Gu%C3%ADa.Completa.Depresion.2013.pdf>. Accessed June 30, 2017.
25. National Institute for Health and Care Excellence. *Depression in adults: recognition and management.* [London]: NICE; 2009 [cited 2017 Jun 30]. Available from: <https://www.nice.org.uk/guidance/cg90/evidenc>. Accessed June 30, 2017.
26. Härter M, Schorr S, Schneider F, eds. *S3-Leitlinie: nationale versorgungsleitlinie unipolare depression langfassung.* 2nd ed. Berlin: Springer; 2015. doi:10.1007/978-3-662-52906-5
27. Instituto de Evaluación de Tecnologías en Salud e Investigación (PE). *Guía de práctica clínica para el tamizaje y el manejo del episodio depresivo leve en el primer nivel de atención.* Lima: EsSalud; 2019. Available from: [http://www.essalud.gob.pe/ietsi/pdfs/tecnologias\\_sanitarias/GPC\\_Depresion\\_V\\_Extensa.pdf](http://www.essalud.gob.pe/ietsi/pdfs/tecnologias_sanitarias/GPC_Depresion_V_Extensa.pdf). Accessed June 30, 2017.
28. Trangle M, Gursky J, Haight R, Hinnenkamp T, Kessler D, Mack N, et al. *Depression in primary care.* Bloomington, MN: ICSI; updated March, 2016. Available from: [https://www.icsi.org/CPGs\\_more/catalog\\_CPGs\\_and\\_more/catalog\\_CPGs/catalog\\_behavioral\\_health\\_CPGs/depression](https://www.icsi.org/CPGs_more/catalog_CPGs_and_more/catalog_CPGs/catalog_behavioral_health_CPGs/depression). Accessed June 30, 2017.

29. American Psychological Association. *Clinical practice guideline for the treatment of depression across three age cohorts*. Washington, DC: APA; 2019 [cite 2017 Jun 30]. Available from: <https://www.apa.org/depression-guideline/guideline.pdf>. Accessed June 30, 2017.
30. Management of Major Depressive Disorder Working Group. *VA/DoD clinical practice guideline for the management of major depressive disorder*. 3rd ed. Washington, DC: US Department of Veterans Affairs, US Department of Defense; 2016.
31. Kaiser Permanente Care Management Institute. *Diagnosis and treatment of depression in adults: 2012 clinical practice guideline*. Oakland (CA): KPCMI; 2012.
32. García-Herrera Pérez Bryan JM, Nogueras Morilla EV, Muñoz Cobos M, Morales Asencio JM. *Guía de práctica clínica para el tratamiento de la depresión en atención primaria*. Málaga: Hospital Regional Universitario “Carlos Haya”; 2011.
33. Working Group of the Clinical Practice Guideline on the Management of Depression in Adults (ES). *Guideline on the management of depression in adults*. [Madrid]: Ministry of Health, Social Services and Equality; 2014.
34. Registered Nurses’ Association of Ontario. *Delirium, dementia, and depression in older adults: assessment and care*. 2nd ed. Toronto (ON): RNAO; 2016.
35. Qaseem A, Barry MJ, Kansagara D. Nonpharmacologic versus pharmacologic treatment of adult patients with major depressive disorder: a clinical practice guideline from the American College of Physicians. *Ann Intern Med*. 2016;164(5):350-359. doi:[10.7326/M15-2570](https://doi.org/10.7326/M15-2570)
36. Instituto Mexicano del Seguro Social. *Guía de práctica clínica gpc: diagnóstico y tratamiento de la depresión en el adulto mayor en el primer nivel de atención*. Ciudad de México: IMSS; 2011.
37. Secretaría de Salud (MX). *Diagnóstico y tratamiento del trastorno depresivo en el adulto*. Ciudad de México: Secretaría de Salud; 2015.
38. Secretaría de Salud (MX). *Diagnóstico y tratamiento del trastorno depresivo en el adulto: intervenciones de enfermería para la detección, atención y control de la depresión en el adulto mayor en los tres niveles de atención*. Ciudad de México: Secretaría de Salud; 2016.

39. Chua HC, Chan LL, Chee KS, Chen YH, Chin SA, Chua PLW, et al. *Depression*. Singapore: Ministry of Health; 2012. Available from: <http://www.smj.org.sg/sites/default/files/5302/5302cpg1.pdf>. Accessed June 30, 2017.
40. Malhi GS, Bassett D, Boyce P, et al. Royal Australian and New Zealand college of psychiatrists clinical practice CPGs for mood disorders. *Aust NZ J Psychiatry*. 2015;49(12):1087-1206. doi:[10.1177/0004867415617657](https://doi.org/10.1177/0004867415617657)
41. Unipolar Depression Guideline Team. *Ambulatory unipolar depression guideline*. Ann Arbor (MI): UMHS; c2021. Available from: <http://michmed-clinical.policystat.com/policy/8093108/>. . Accessed June 30, 2017.
42. Driot D, Bismuth M, Maurel A, et al. Management of first depression or generalized anxiety disorder episode in adults in primary care: a systematic metareview. *Presse Med*. 2017;46(12 Pt 1):1124-1138. doi:[10.1016/j.lpm.2017.10.010](https://doi.org/10.1016/j.lpm.2017.10.010)
43. Bauer M, Pfennig A, Severus E, et al. World federation of societies of biological psychiatry (WFSBP) CPGs for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. *World J Biol Psychiatry*. 2013;14(5):334-385. doi:[10.3109/15622975.2013.804195](https://doi.org/10.3109/15622975.2013.804195)
44. Kennedy SH, Lam RW, McIntyre RS, et al. Canadian network for mood and anxiety treatments (CANMAT), 2016, clinical CPGs for the management of adults with major depressive disorder: section 3: pharmacological treatments. *Can J Psychiatry*. 2016;61(9):540-560. doi:[10.1177/0706743716659417](https://doi.org/10.1177/0706743716659417)
45. Dua T, Barbui C, Clark N, et al. Evidence-based CPGs for mental, neurological, and substance use disorders in low-and middle-income countries: summary of WHO recommendations. *PLoS Med*. 2011;8(11):e1001122. doi:[10.1371/journal.pmed.1001122](https://doi.org/10.1371/journal.pmed.1001122)
46. McIntyre RS, Suppes T, Tandon R, Ostacher M. Florida best practice psychotherapeutic medication CPGs for adults with major depressive disorder. *J Clin Psychiatry*. 2017;78(6):703-713. doi:[10.4088/JCP.16cs10885](https://doi.org/10.4088/JCP.16cs10885)
47. Bauer M, Severus E, Köhler S, Whybrow PC, Angst J, Möller, H-J. World federation of societies of biological psychiatry (WFSBP) CPGs for biological treatment of unipolar depressive disorders: part 2: maintenance treatment of



- major depressive disorder-update 2015. *World J Biol Psychiatry*. 2015;16(2):76-95. doi:[10.3109/15622975.2014.1001786](https://doi.org/10.3109/15622975.2014.1001786)
48. Malaysian Health Technology Assessment Section. *Management of major depressive disorder*. 2nd ed. Putrajaya: Ministry of Health; 2019.
49. Gelenberg AJ, Freeman MP, Markowitz JC, et al. Practice guideline for the treatment of patients with major depressive disorder. 3th ed. Washington, DC: American Psychological Association; 2010. Available from: [https://psychiatryonline.org/pb/assets/raw/sitewide/practice\\_CPGs/CPGs/mdd.pdf](https://psychiatryonline.org/pb/assets/raw/sitewide/practice_CPGs/CPGs/mdd.pdf). Accessed August 14, 2017.
50. NHG-werkgroep. *Depressie: versie 3.1* [Under review]. Available from: <https://richtlijnen.nhg.org/standaarden/depressie>. Accessed March 18, 2021.
51. Cleare A, Pariante CM, Young AH, et al. Evidence-based CPGs for treating depressive disorders with antidepressants: a revision of the 2008 British association for psychopharmacology CPGs. *J Psychopharmacol*. 2015;29(5):459-525. doi:[10.1177/0269881115581093](https://doi.org/10.1177/0269881115581093)
52. Won E, Park S-C, Han K-M, et al. Evidence-based, pharmacological treatment guideline for depression in Korea, revised edition. *J Korean Med Sci*. 2014;29:468-484. <https://doi.org/10.3346/jkms.2014.29.4.468>
53. Suomalainen Lääkäriseura Duodecim. *Depressio*. Available from: <https://www.kaypahoito.fi/hoi50023>. Accessed September 18, 2021.
54. Ruberto VL, Jha MK, Murrough JW. Pharmacological treatments for patients with treatment-resistant depression. *Pharmaceuticals*. 2020;13(6):116. <https://doi.org/10.3390/ph13060116>
55. British Columbia. *Major depressive disorder in adults: diagnosis and management*. British Columbia: BC; 2013. Available FROM: <https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/bc-guidelines/depression-in-adults>. Accessed January 24, 2017.
56. Giakoumatos CI, Osser D. The psychopharmacology algorithm project at the Harvard South Shore Program: an update on unipolar nonpsychotic depression. *Harv Rev Psychiatry*. 2019;27(1):33-52. doi:[10.1097/HRP.0000000000000197](https://doi.org/10.1097/HRP.0000000000000197)
57. Bennabi D, Charpeaud T, Yroni A, et al. Clinical CPGs for the management of treatment-resistant depression: French recommendations from experts, the French association for biological psychiatry and neuropsychopharmacology and

- the foundation FondaMental. *BMC Psychiatry*. 2019;19(1):262.  
doi:[10.1186/s12888-019-2237-x](https://doi.org/10.1186/s12888-019-2237-x)
58. Okasha A, Alkdhari S, Al Sharqi A, et al. Arab treatment guidelines for the management of major depressive disorder. *Arab J Psychiatry*. 2017;28(2): 97-117. doi:[10.12816/0041709](https://doi.org/10.12816/0041709)
59. Dodd S, Mitchell PB, Bauer M, et al. Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: an international consensus statement. *World J Biol Psychiatry*. 2018;19(5):330-348. doi:[10.1080/15622975.2017.1379609](https://doi.org/10.1080/15622975.2017.1379609)
60. Bauer M, Severus E, Möller H-J, et al. Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines. *Int J Psychiatry Clin Pract*. 2017;21(3):166-176. doi:[10.1080/13651501.2017.1306082](https://doi.org/10.1080/13651501.2017.1306082)
61. Bennabi D, Yroni A, Charpeaud T, et al. Clinical guidelines for the management of depression with specific comorbid psychiatric conditions French recommendations from experts: the French Association for Biological Psychiatry and Neuropsychopharmacology and the foundation FondaMental. *BMC Psychiatry*. 2019;19(1):50. doi:[10.1186/s12888-019-2025-7](https://doi.org/10.1186/s12888-019-2025-7)
62. Sakurai H, Uchida H, Kato M, Suzuki T, Baba H, Watanabe K, et al. Pharmacological management of depression: Japanese expert consensus. *J Affect Disord*. 2020;266:626-632. doi:[10.1016/j.jad.2020.01.149](https://doi.org/10.1016/j.jad.2020.01.149)
63. Emsley R, Flisher AJ, Grobler G, Seedat S, Szabo CP. The South African society of psychiatrists (SASOP) treatment CPGs for psychiatric disorders. *S Afr J Psychiatr*. 2013;19(3):2. doi:[10.4102/sajpsy psychiatry.v19i3.942](https://doi.org/10.4102/sajpsy psychiatry.v19i3.942)
64. Connolly KR, Thase ME. If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. *Drugs*. 2011;71(1):43-64. doi:[10.2165/11587620-000000000-00000](https://doi.org/10.2165/11587620-000000000-00000)
65. Wang HR, Bahk W-M, Park Y-M, et al. Korean medication algorithm for depressive disorder: comparisons with other treatment CPGs. *Psychiatry Investig*. 2014;11(1):1-11. doi:[10.4306/pi.2014.11.1.1](https://doi.org/10.4306/pi.2014.11.1.1)
66. Park LT, Zarate CA Jr. Depression in the primary care setting. *N Engl J Med*. 2019;380(6):559-568. doi:[10.1056/NEJMcp1712493](https://doi.org/10.1056/NEJMcp1712493)
67. Voineskos D, Daskalakis ZJ, Blumberger DM. Management of treatment-resistant depression: challenges and strategies. *Neuropsychiatr Dis Treat*. 2020;16:221-234. doi:[10.2147/NDT.S198774](https://doi.org/10.2147/NDT.S198774)

68. Voytenko V, Nykamp L, Achtyes E, et al. Evidence-based practice guideline for the treatment of adult patients with depressive disorders: part I: psychiatric management. *Psychiatr Psychol Klin*. 2018;18(3):234-241. doi:[10.15557/PiPK.2018.0029](https://doi.org/10.15557/PiPK.2018.0029)
69. Piotrowski P, Gondek TM, Rymaszewska J, et al. Guidelines of the Polish Psychiatric Association: wroclaw division, the Polish society of family medicine and the college of family physicians in Poland for diagnosis and treatment of depressive disorders in primary health care. *Fam Med Prim Care Rev*. 2017;19(3):335-346. doi:[10.5114/fmpcr.2017.69300](https://doi.org/10.5114/fmpcr.2017.69300)
70. Bayes A, Parker G. How to choose an antidepressant medication. *Acta Psychiatr Scand*. 2019;139(3):280-291. doi:[10.1111/acps.13001](https://doi.org/10.1111/acps.13001)
71. Malhi GS, Hitching R, Berk M, Boyce P, Porter R, Fritz K. Pharmacological management of unipolar depression. *Acta Psychiatr Scand Suppl*. 2013;127(suppl 443):6-23. doi:[10.1111/acps.12122](https://doi.org/10.1111/acps.12122)
72. Doumy O, Bennabi D, El-Hage W, et al. Dépression résistante: les stratégies de potentialisation. *Presse Med*. 2016;45(3):338-349. doi:[10.1016/j.lpm.2016.02.004](https://doi.org/10.1016/j.lpm.2016.02.004)
73. Mulsant BH, Blumberger DM, Ismail Z, Rabheru K, Rapoport MJ. A systematic approach to pharmacotherapy for geriatric major depression. *Clin Geriatr Med*. 2014;30(3):517-534. doi:[10.1016/j.cger.2014.05.002](https://doi.org/10.1016/j.cger.2014.05.002)
74. Gałęcki P, Bliźniewska-Kowalska K. Treatment-resistant depression – recommendations of the National Consultant in the field of psychiatry. *Psychiatr Pol*. 2021;55(1):7–21. doi:[10.12740/PP/OnlineFirst/115208](https://doi.org/10.12740/PP/OnlineFirst/115208)
75. Avasthi A, Grover S. Clinical practice CPGs for management of depression in elderly. *Indian J Psychiatry*. 2018;60(suppl 3):S341-S362. doi:[10.4103/0019-5545.224474](https://doi.org/10.4103/0019-5545.224474)
76. Möller HJ, Bitter I, Bobes J, et al. Position statement of the European psychiatric association (EPA) on the value of antidepressants in the treatment of unipolar depression. *Eur Psychiatry*. 2012;27(2):114-128. doi:[10.1016/j.eurpsy.2011.08.002](https://doi.org/10.1016/j.eurpsy.2011.08.002)
77. Charpeaud T, Molierè F, Bubrowszky M, et al. Dépression résistante: les stratégies de changement et d'association de médicaments antidépresseurs. *Presse Med*. 2016;45(3):329-337. doi:[10.1016/j.lpm.2016.02.003](https://doi.org/10.1016/j.lpm.2016.02.003)

78. Busch FN, Sandberg LS. Combined treatment of depression. *Psychiatr Clin North Am.* 2012;35(1):165-179. doi:[10.1016/j.psc.2011.10.002](https://doi.org/10.1016/j.psc.2011.10.002)
79. Mathys M, Mitchell BG. Targeting treatment-resistant depression. *J Pharm Pract.* 2011;24(6):520-533. doi:[10.1177/0897190011426972](https://doi.org/10.1177/0897190011426972)
80. Taylor WD. Depression in the elderly. *N Engl J Med.* 2014;371(13):1228-1236. doi:[10.1056/NEJMc1402180](https://doi.org/10.1056/NEJMc1402180)
81. Gartlehner G, Thaler K, Hill S, Hansen RA. How should primary care doctors select which antidepressants to administer?. *Curr Psychiatry Rep.* 2012;14(4):360-369. doi:[10.1007/s11920-012-0283-x](https://doi.org/10.1007/s11920-012-0283-x)
82. Pereira Sanchez V, Molero Santos P. Protocolo diagnóstico y terapéutico de la depresión. *Medicine.* 2019;12(86):5070-5074. doi:[10.1016/j.med.2019.09.015](https://doi.org/10.1016/j.med.2019.09.015)
83. Gautam S, Jain A, Gautam M, Vahia VN, Grover S. Clinical practice CPGs for the management of depression. *Indian J Psychiatry.* 2017;59(suppl 1):S34-S50. doi:[10.4103/0019-5545.196973](https://doi.org/10.4103/0019-5545.196973)
84. Halaris A. A primary care focus on the diagnosis and treatment of major depressive disorder in adults. *J Psychiatr Pract.* 2011;17(5):340-350. doi:[10.1097/01.pra.0000405364.90043.bd](https://doi.org/10.1097/01.pra.0000405364.90043.bd)
85. Patejuk-Mazurek I. Selected antidepressants and anxiolytics: practical guidelines and case studies. *Psychiatria.* 2017;14(3):135-142. Polish. Available from: <https://journals.viamedica.pl>. Accessed January 24, 2017.